Drug profile · INN
mesoridazine besylate
SERENTIL
mesoridazine besylate (SERENTIL) is a dopamine d2 receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — mesoridazine besylate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
mesoridazine besylate (SERENTIL) is a dopamine d2 receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Dopamine D2 receptor antagonist
Primary target: D(2) dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is mesoridazine besylate?
mesoridazine besylate (SERENTIL) is a dopamine d2 receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for mesoridazine besylate?
SERENTIL is a marketed brand name for mesoridazine besylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mesoridazine besylate?
mesoridazine besylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.